Validated Stability Indicating HPTLC Method for the Estimation of Amoxapine in Different Stress Conditions

Author(s): Shweta G. Rangari, Nishikant A. Raut*, Pradip W. Dhore.

Journal Name: Current Pharmaceutical Analysis

Volume 15 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: The unstable and/or toxic degradation products may form due to degradation of drug which results into loss of therapeutic activity and lead to life threatening condition. Hence, it is important to establish the stability characteristics of drug in various conditions such as in temperature, light, oxidising agent and susceptibility across a wide range of pH values.

Introduction: The aim of the proposed study was to develop simple, sensitive and economic stability indicating high performance thin layer chromatography (HPTLC) method for the quantification of Amoxapine in the presence of degradation products.

Methods: Amoxapine and its degraded products were separated on precoated silica gel 60F254 TLC plates by using mobile phase comprising of methanol: toluene: ammonium acetate (6:3:1, v/v/v). The densitometric evaluation was carried out at 320 nm in reflectance/absorbance mode. The degradation products obtained as per ICH guidelines under acidic, basic and oxidative conditions have different Rf values 0.12, 0.26 and 0.6 indicating good resolution from each other and pure drug with Rf: 0.47. Amoxapine was found to be stable under neutral, thermal and photo conditions.

Results: The method was validated as per ICH Q2 (R1) guidelines in terms of accuracy, precision, ruggedness, robustness and linearity. A good linear relationship between concentration and response (peak area and peak height) over the range of 80 ng/spot to 720 ng/spot was observed from regression analysis data showing correlation coefficient 0.991 and 0.994 for area and height, respectively. The limit of detection (LOD) and limit of quantitation (LOQ) for area were found to be 1.176 ng/mL and 3.565 ng/mL, whereas for height, 50.063 ng/mL and 151.707 ng/mL respectively.

Conclusion: The statistical analysis confirmed the accuracy, precision and selectivity of the proposed method which can be effectively used for the analysis of amoxapine in the presence of degradation products.

Keywords: Amoxapine, HPTLC, stability indicating, validation, stress degradation, TCA.

[1]
Melo, S.; Melo, M.; Silveira, D.; Simeoni, L. Advice on degradation product in pharmaceuticals: a toxicological evaluation. PDA J. Pharm. Sci.and Tech., 2014, 68, 221-238.
[2]
Bajaj, S.; Singla, D.; Sakhuja, N. Stability testing of pharmaceutical product. J. Appl. Pharm. Sci., 2013, 2, 129-138.
[3]
Al-Rayes, I. Spectrophotometric and fluorimetric methods for determination of selective reuptake inhibitors using derivatizing reagents.. PhD Thesis, King Saud University, Riyadh, 2009.
[4]
Jue, S.; Dawson, G.; Brogden, R. amoxapine: A review of its pharmacology and efficacy in depressant states. Drug Eval., 1982, 24, 1-23.
[5]
Apiquian, R.; Uiioa, E.; Fresan, A.; Loyzaga, C.; Nicolini, H.; Kapur, S. amoxapine shows atypical antipsychotic effect in patients with schizophrenia: results from a prospective open-label study. Schizophr. Res., 2002, 59, 35-39.
[6]
Tassel, J.; Hassan, F. Liquid chromatographic determination of amoxapine and 8-hydroamoxapine in human serum. Clin. Chem., 1982, 28(10), 2154-2162.
[7]
Selinger, K.; Lebel, G.; Hill, H.; Anslow, J. A high –performance liquid chromatographic method for the analysis of amoxapine in human plasma. J. Pharm. Biomed. Anal., 1989, 8, 1001-1007.
[8]
Vijaykrishna, A.; Patel, S.; Ahmad, M.; Shetty, S.; Kuppast, L.; Anilkumar, S.; Ravi, M. RP-HPLC method development and validation for estimation of amoxapine in tablet dosage form. World J. Pharm. Pharm. Sci., 2015, 4(1), 1113-1119.
[9]
Gupta, M.; Jain, A.; Verna, K. Determination of amoxapine and nortriptylline liquid-liquid microextraction and high-performance liquid chromatography. J. Sep. Sci., 2010, 33, 3774-3780.
[10]
Steven, H.; Wong, Y.; Waugh, W. Determination of the antidepressant maprotiline and amoxapine and their metabolite in plasma by liquid chromatography. Clin. Chem., 1983, 29(2), 314-318.
[11]
Zimmer, J.; Needham, S.; Christianson, C.; Piekarski, C.; Sheaff, C.; Huie, K.; Reed, A.; Takahashi, L. Validation of HPLC-MS/MS methods for analysis of loxapine, amoxapine, 7-OH-loxapine, 8-OH-loxapine and N-oxide in human plasma. Alturas Analytics. Inc., 2010, 2(12), 1989-2000.
[12]
Patel, S.; Vijaykrishna, C.; Shetty, S.; Ahmad, M. Development and validation of first order derivative spectrophotometric method for estimation of amoxapine in bulk and tablet dosage form. Int. J. Univers. Pharm. Bio. Sci., 2015, 4(1), 29-35.
[13]
Karasakal, A.; Ulu, S. Development and validation of a sensitive spectrofluorimetric method for the determination of amoxapine in human plasma and urine. J. Biol. Chem. Lumin., 2013, 29, 284-287.
[14]
Titier, K.; Casaing, N.; Le-Deodic, M.; Le-bars, D.; Moore, N.; Molimard, M. Quantification of tricyclic antidepressant and monoamine oxidase inhibitors by high –performance liquid chromatography-tandem mass spectrometry in whole blood. J. Anal. Toxicol., 2007, 31, 200-207.
[15]
Bimal, N.; Sekhon, B. High performance thin layer chromatography: application in pharmaceutical sciences. Ph. Tech. Med., 2013, 2(4), 323-333.
[16]
Singh, S.; Bakshi, M. Stress tests to determined inherent stability of drugs. Pharm. Technol. On-Line , 2000, 1-14.
[17]
Renger, B.; Vegh, Z.; Ferenczi-Fodor, K. Validation of thin layer and high performance thin layer chromatographic methods. J. Chromatogr. A, 2011, 1218, 2712-2721.
[18]
International Conference of Harmonization; Stability testing of new drug substances and product: Geneva 2003.
[19]
International Conference of Harmonization; Stability testing: Photostability testing of new drug substances and products: Geneva 1996.
[20]
International Conference of Harmonization; Q2 (R1) validation of analytical procedure: methodology: Geneva 1996.
[21]
Shewiyo, D.; Kaale, E.; Risha, P.; Dejaegher, B.; Smeyers-Verbeke, J.; Heyden, Y. HPTLC methods to assay active ingredients in pharmaceutical formulation: A review of the method development and validation step. J. Pharm. Biomed. Anal., 2012, 66, 11-23.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 3
Year: 2019
Page: [273 - 279]
Pages: 7
DOI: 10.2174/1573412914666171228163122
Price: $58

Article Metrics

PDF: 10
HTML: 3
PRC: 1